Cyclodextrin-PEG Therapy for Adult Hippocampal Neurogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The adult human brain's inability to generate replacement neurons leads to irreversible neurological diseases and conditions such as Kabuki syndrome, which causes hippocampal dysfunction, intellectual disability, and neurodegenerative disorders, with no known treatments to stimulate post-natal hippocampal functions or neurogenesis.
Innovation Solution
A composition comprising cyclodextrin and polyethylene glycol (PEG), administered in specific ratios, stimulates neurogenesis by increasing the proliferation of neural precursors and neurogenesis in the hippocampus, enhancing learning, memory, and reducing tactile allodynia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the adult human brain attempts to generate replacement neurons, then neurogenesis would occur to treat neurological diseases, but the adult human brain lacks the capability to generate replacement cells after the developmental period
Solution Approach 1:
The patent changes the chemical parameters of the brain environment by administering cyclodextrin and PEG compounds that modify molecular interactions, thereby activating neurogenesis pathways that are normally dormant in adult brains. This parameter change enables the brain to generate replacement neurons despite its natural inability to do so after development.
Solution Approach 2:
The patent introduces cyclodextrin and PEG compounds as intermediary substances that mediate between the administered treatment and the brain's neural progenitor cells. These intermediaries facilitate the activation of neurogenesis by interacting with cellular components and triggering the differentiation and proliferation of neural cells.
2Stability of the object's composition
If no treatment is administered, then the brain maintains its natural state, but neurological diseases progress irreversibly due to neuron loss
Solution Approach 1:
The patent applies preliminary action by administering cyclodextrin and PEG compounds before significant neurological damage occurs. This preventive treatment stimulates neurogenesis in advance, creating a reservoir of replacement neurons that can compensate for future neuron loss and prevent irreversible disease progression.
Solution Approach 2:
The patent converts the harmful process of neuron loss into a beneficial outcome by stimulating the brain's latent capacity for neurogenesis. The treatment transforms the natural inability to regenerate neurons into an active regenerative process, turning the brain's vulnerability into a therapeutic opportunity.
3Reliability
If cyclodextrin and PEG are administered to stimulate neurogenesis, then DCX positive neuroblasts increase by 20%, but the treatment complexity increases
Solution Approach 1:
The patent uses composite materials by combining cyclodextrin and PEG in specific ratios to create a synergistic treatment formulation. This composite approach leverages the complementary properties of both compounds, where cyclodextrin provides molecular inclusion capabilities and PEG provides solubility and bioavailability enhancement, achieving effective neurogenesis stimulation while managing treatment complexity through rational formulation design.
Data Source
AI summary
Aspects of the invention are directed to methods of stimulating or promoting neurogenesis by administering to a subject of a composition comprising a cyclodextrin and a polyethylene glycol to alleviate learning, memory and cognitive deficits present in subjects afflicted with various brain disorders or from neurodegenerative disorder associated with aging.